title: [Non oncologic applications of molecular targeted therapies].
abstract: Significant improvements in the knowledge of cancer biology have permitted the development of new molecular targeted therapies. Meanwhile, a better understanding of the physiology of various non-cancerous diseases has allowed developing these agents in other areas. This review intends to illustrate these perspectives through examples corresponding to different strategies of molecular-targeted therapies : use of a monoclonal antibody binding a receptor (rituximab and rheumatoid arthritis) or a ligand (bevacizumab and age-related macular degeneration), tyrosine kinase inhibitor (imatinib and systemic sclerosis) or inhibitor of cytoplasmic signal transduction pathways (immunosuppressive and antiproliferative effects of mammalian target of rapamycin [mTOR] inhibitors). Clinical results can draw today what could become molecular medicine of tomorrow.
authors.affiliation: Groupe hospitalier Pitié-Salpêtrière - Charles-Foix, service d'oncologie médicale, Paris Cedex, France.
authors.forename: Wassef
authors.initials: W
authors.lastname: Khaled
authors.forename: Thibault
authors.initials: T
authors.lastname: de la Motte Rouge
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Amirault
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001549:Benzamides; D000068258:Bevacizumab; D054855:Drug-Eluting Stents; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008268:Macular Degeneration / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068258:Bevacizumab; D000069283:Rituximab; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases